166 related articles for article (PubMed ID: 36982651)
1. Synergistic Interaction of the Class IIa HDAC Inhibitor CHDI0039 with Bortezomib in Head and Neck Cancer Cells.
Schrenk C; Bollmann LM; Haist C; Bister A; Wiek C; Wecker M; Roth D; Petzsch P; Köhrer K; Hamacher A; Hanenberg H; Fluegen G; Kassack MU
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982651
[TBL] [Abstract][Full Text] [Related]
2. 5-(Trifluoromethyl)-1,2,4-oxadiazole (TFMO)-based highly selective class IIa HDAC inhibitors exhibit synergistic anticancer activity in combination with bortezomib.
Asfaha Y; Bollmann LM; Skerhut AJ; Fischer F; Horstick N; Roth D; Wecker M; Mammen C; Smits SHJ; Fluegen G; Kassack MU; Kurz T
Eur J Med Chem; 2024 Jan; 263():115907. PubMed ID: 37979441
[TBL] [Abstract][Full Text] [Related]
3. Effects of novel HDAC inhibitors on urothelial carcinoma cells.
Kaletsch A; Pinkerneil M; Hoffmann MJ; Jaguva Vasudevan AA; Wang C; Hansen FK; Wiek C; Hanenberg H; Gertzen C; Gohlke H; Kassack MU; Kurz T; Schulz WA; Niegisch G
Clin Epigenetics; 2018 Jul; 10(1):100. PubMed ID: 30064501
[TBL] [Abstract][Full Text] [Related]
4. Synergistic induction of apoptosis in resistant head and neck carcinoma and leukemia by alkoxyamide-based histone deacetylase inhibitors.
Alves Avelar LA; Schrenk C; Sönnichsen M; Hamacher A; Hansen FK; Schliehe-Diecks J; Borkhardt A; Bhatia S; Kassack MU; Kurz T
Eur J Med Chem; 2021 Feb; 211():113095. PubMed ID: 33360560
[TBL] [Abstract][Full Text] [Related]
5. The Novel Class IIa Selective Histone Deacetylase Inhibitor YAK540 Is Synergistic with Bortezomib in Leukemia Cell Lines.
Bollmann LM; Skerhut AJ; Asfaha Y; Horstick N; Hanenberg H; Hamacher A; Kurz T; Kassack MU
Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362189
[TBL] [Abstract][Full Text] [Related]
6. Effect of the histone deacetylase inhibitor resminostat on head and neck squamous cell carcinoma cell lines.
Enzenhofer E; Kadletz L; Stanisz I; Kotowski U; Seemann R; Schmid R; Thurnher D; Heiduschka G
Head Neck; 2017 May; 39(5):900-907. PubMed ID: 28170128
[TBL] [Abstract][Full Text] [Related]
7. Novel alkoxyamide-based histone deacetylase inhibitors reverse cisplatin resistance in chemoresistant cancer cells.
Asfaha Y; Schrenk C; Alves Avelar LA; Lange F; Wang C; Bandolik JJ; Hamacher A; Kassack MU; Kurz T
Bioorg Med Chem; 2020 Jan; 28(1):115108. PubMed ID: 31787463
[TBL] [Abstract][Full Text] [Related]
8. Class I-Histone Deacetylase (HDAC) Inhibition is Superior to pan-HDAC Inhibition in Modulating Cisplatin Potency in High Grade Serous Ovarian Cancer Cell Lines.
Bandolik JJ; Hamacher A; Schrenk C; Weishaupt R; Kassack MU
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234549
[TBL] [Abstract][Full Text] [Related]
9. Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors.
Zang Y; Kirk CJ; Johnson DE
Cancer Biol Ther; 2014 Sep; 15(9):1142-52. PubMed ID: 24915039
[TBL] [Abstract][Full Text] [Related]
10. Novel α,β-unsaturated hydroxamic acid derivatives overcome cisplatin resistance.
Pflieger M; Hamacher A; Öz T; Horstick-Muche N; Boesen B; Schrenk C; Kassack MU; Kurz T
Bioorg Med Chem; 2019 Oct; 27(19):115036. PubMed ID: 31431326
[TBL] [Abstract][Full Text] [Related]
11. Nuclear factor-kappaB p65 small interfering RNA or proteasome inhibitor bortezomib sensitizes head and neck squamous cell carcinomas to classic histone deacetylase inhibitors and novel histone deacetylase inhibitor PXD101.
Duan J; Friedman J; Nottingham L; Chen Z; Ara G; Van Waes C
Mol Cancer Ther; 2007 Jan; 6(1):37-50. PubMed ID: 17237265
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of HDAC6 Protein Enhances Bortezomib-induced Apoptosis in Head and Neck Squamous Cell Carcinoma (HNSCC) by Reducing Autophagy.
Chang I; Wang CY
J Biol Chem; 2016 Aug; 291(35):18199-209. PubMed ID: 27369083
[TBL] [Abstract][Full Text] [Related]
13. Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.
Caponigro F; Di Gennaro E; Ionna F; Longo F; Aversa C; Pavone E; Maglione MG; Di Marzo M; Muto P; Cavalcanti E; Petrillo A; Sandomenico F; Maiolino P; D'Aniello R; Botti G; De Cecio R; Losito NS; Scala S; Trotta A; Zotti AI; Bruzzese F; Daponte A; Calogero E; Montano M; Pontone M; De Feo G; Perri F; Budillon A
BMC Cancer; 2016 Nov; 16(1):918. PubMed ID: 27884140
[TBL] [Abstract][Full Text] [Related]
14. Azacitidine, as a DNMT Inhibitor Decreases hTERT Gene Expression and Telomerase Activity More Effective Compared with HDAC Inhibitor in Human Head and Neck Squamous Cell Carcinoma Cell Lines.
Atri S; Nasoohi N; Hodjat M
Curr Mol Pharmacol; 2021; 14(1):60-67. PubMed ID: 32394848
[TBL] [Abstract][Full Text] [Related]
15. Synthesis of Peptoid-Based Class I-Selective Histone Deacetylase Inhibitors with Chemosensitizing Properties.
Krieger V; Hamacher A; Cao F; Stenzel K; Gertzen CGW; Schäker-Hübner L; Kurz T; Gohlke H; Dekker FJ; Kassack MU; Hansen FK
J Med Chem; 2019 Dec; 62(24):11260-11279. PubMed ID: 31762274
[TBL] [Abstract][Full Text] [Related]
16. PS-341 and histone deacetylase inhibitor synergistically induce apoptosis in head and neck squamous cell carcinoma cells.
Kim J; Guan J; Chang I; Chen X; Han D; Wang CY
Mol Cancer Ther; 2010 Jul; 9(7):1977-84. PubMed ID: 20571067
[TBL] [Abstract][Full Text] [Related]
17. Alteration of cancer stem cell-like phenotype by histone deacetylase inhibitors in squamous cell carcinoma of the head and neck.
Chikamatsu K; Ishii H; Murata T; Sakakura K; Shino M; Toyoda M; Takahashi K; Masuyama K
Cancer Sci; 2013 Nov; 104(11):1468-75. PubMed ID: 23992541
[TBL] [Abstract][Full Text] [Related]
18. Changes in histone deacetylase (HDAC) expression patterns and activity of HDAC inhibitors in urothelial cancers.
Niegisch G; Knievel J; Koch A; Hader C; Fischer U; Albers P; Schulz WA
Urol Oncol; 2013 Nov; 31(8):1770-9. PubMed ID: 22944197
[TBL] [Abstract][Full Text] [Related]
19. Zerumbone acts as a radiosensitizer in head and neck squamous cell carcinoma.
Schnoell J; Stanisz I; Jank BJ; Stanek V; Schmid R; Brunner M; Heiduschka G; Kotowski U
Invest New Drugs; 2022 Apr; 40(2):224-231. PubMed ID: 34613571
[TBL] [Abstract][Full Text] [Related]
20. Alkoxyurea-Based Histone Deacetylase Inhibitors Increase Cisplatin Potency in Chemoresistant Cancer Cell Lines.
Stenzel K; Hamacher A; Hansen FK; Gertzen CGW; Senger J; Marquardt V; Marek L; Marek M; Romier C; Remke M; Jung M; Gohlke H; Kassack MU; Kurz T
J Med Chem; 2017 Jul; 60(13):5334-5348. PubMed ID: 28581289
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
